AstraZeneca and Merck & Co., Inc. presented data, which showed clinical improvement in survival with Lynparza in combination with abiraterone.
The study covered metastatic castration-resistant prostate cancer. Lynparza is being jointly developed and commercialized by AstraZeneca and Merck.
The findings were published online in the Lancet Oncology.
Noel Clarke, professor of Urological Oncology, Christie NHS Foundation Trust, Manchester, UK, said: “This is the first time we have seen an improvement with the use of a PARP inhibitor in combination with abiraterone in patients with metastatic castration-resistant prostate cancer and this effect may be independent of HRR status. The data suggest this therapeutic combination may be a promising new treatment approach for this aggressive disease.”
Sean Bohen, executive vice president, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “A previous trial demonstrated improvements in response rates with Lynparza monotherapy in metastatic castration-resistant patients with HRR mutations. The Study 08 combination data suggests that regardless of their mutation status, men with metastatic castration-resistant prostate cancer may potentially benefit from Lynparza in combination with abiraterone.”
